Trial Profile
Phase I Dose Escalation of Gleevec [imatinib] in Combination With RAD001 [everolimus] Plus Hydroxyurea [hydroxycarbamide] for Patients With Recurrent Malignant Glioma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Imatinib (Primary) ; Hydroxycarbamide
- Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma
- Focus Adverse reactions
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Nov 2008 Status changed from recruiting to active, no longer recruiting, reported by ClinicalTrials.gov.
- 25 Feb 2008 New trial record.